← All candidates
107 insider filings on record.
107 filings on record.
ELVNEnliven Therapeutics, Inc.
NasdaqGS · Healthcare · $3.60B
$49.12
-7.95% · Sep 16
107 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 56 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$3.60B
Float
60.5M
83% public
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
3 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
102 more transactions on Pro →Context
Wall St
$73.90 avg target
+50.4% vs today · 10 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q2 '26−$0.49 act−$0.11
Q1 '26−$0.38 act+$0.03
Q4 '25−$0.48 act−$0.01
Q3 '25−$0.32 act+$0.15
Coverage
Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value LagsSimply Wall St. · 07-04What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%Motley Fool · 06-27What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% RallyMotley Fool · 06-27Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?
The file stays open
107 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice